Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

1.

Genetic predictors of MEK dependence in non-small cell lung cancer.

Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB.

Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223.

PMID:
19010912
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

PMID:
22964644
[PubMed - indexed for MEDLINE]
3.

Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.

Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades CS, Wellmann A, Mitsiades N.

Endocr Relat Cancer. 2009 Jun;16(2):565-72. doi: 10.1677/ERC-08-0101. Epub 2009 Feb 3.

PMID:
19190079
[PubMed - indexed for MEDLINE]
Free Article
4.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.

PMID:
22773810
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R.

Ann Oncol. 2014 Jan;25(1):138-42. doi: 10.1093/annonc/mdt495. Epub 2013 Dec 1.

PMID:
24297085
[PubMed - indexed for MEDLINE]
Free Article
6.

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.

Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, Ren-Heidenreich L, Shi B, Ren H, Chu X, Kang J, Wang W, Xu J, Tang K, Yang H, Zheng Y, He J, Yu G, Liang N.

Br J Cancer. 2014 May 27;110(11):2812-20. doi: 10.1038/bjc.2014.210. Epub 2014 Apr 17.

PMID:
24743704
[PubMed - indexed for MEDLINE]
7.

Molecular alterations in non-small cell lung carcinomas of the young.

VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.

Hum Pathol. 2014 Dec;45(12):2379-87. doi: 10.1016/j.humpath.2014.08.005. Epub 2014 Sep 2.

PMID:
25288236
[PubMed - indexed for MEDLINE]
8.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

PMID:
22511580
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.

Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, Jacks T, Neel BG, Lauffenburger DA.

Cancer Res. 2010 May 1;70(9):3843-50. doi: 10.1158/0008-5472.CAN-09-3421. Epub 2010 Apr 20.

PMID:
20406974
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.

PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690.

PMID:
17973573
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.

Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L.

Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.

PMID:
23930206
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.

Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Int J Cancer. 2012 Apr 15;130(8):1733-44. doi: 10.1002/ijc.26164. Epub 2011 Aug 3.

PMID:
21544811
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK.

Cancer Res. 2007 May 15;67(10):4933-9.

PMID:
17510423
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.

Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.

PMID:
23833300
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.

Lewandowska MA, Jóźwicki W, Jochymski C, Kowalewski J.

Oncol Rep. 2013 Sep;30(3):1045-52. doi: 10.3892/or.2013.2579. Epub 2013 Jul 1.

PMID:
23817662
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
[PubMed - indexed for MEDLINE]
17.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

PMID:
20668238
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.

Tuononen K, Mäki-Nevala S, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI, Hannula S, Lagström S, Ellonen P, Knuuttila A, Knuutila S.

Genes Chromosomes Cancer. 2013 May;52(5):503-11. doi: 10.1002/gcc.22047. Epub 2013 Jan 30.

PMID:
23362162
[PubMed - indexed for MEDLINE]
19.

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y.

Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2.

PMID:
24200637
[PubMed - indexed for MEDLINE]
Free Article
20.

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K.

Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18.

PMID:
19018267
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk